Curative Biosciences, Inc. (CBDX) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCurative Biosciences, Inc. (CBDX) trades at $0.0001. Curative Biosciences, Inc. is a healthcare company focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. The company aims to manufacture and market natural health products within the medical cannabis industry. Sector: Healthcare.
Price as of · Last analyzed: Mar 18, 2026Analyst Coverage for CBDX: CBDX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Curative Biosciences, Inc. (CBDX) Healthcare & Pipeline Overview
Curative Biosciences, Inc. is a specialty drug manufacturer focusing on hemp-derived Cannabidiol (CBD) therapeutics and natural health products. Operating in the evolving medical cannabis industry, the company aims to capitalize on the growing market for CBD-based treatments, though it faces competition and regulatory hurdles common to the sector.
What Is the Investment Thesis for CBDX?
Curative Biosciences, Inc. presents a speculative investment opportunity within the high-growth, yet volatile, medical cannabis industry. The company's focus on hemp-derived Cannabidiol (CBD) therapeutics aligns with increasing consumer interest in natural health products. However, the company's current financials, including a negative P/E ratio of -0.03 and a market cap of $0.00B, indicate significant risk. Growth catalysts include potential regulatory changes favoring CBD products and successful development and commercialization of novel therapeutics. The company's high beta of 64.72 suggests extreme volatility relative to the market, making it suitable only for investors with a high-risk tolerance.
Based on FMP financials and quantitative analysis
CBDX Key Highlights
Curative Biosciences operates in the high-growth medical cannabis industry, focusing on hemp-derived Cannabidiol (CBD) therapeutics.
- The company intends to manufacture and market natural health products, targeting consumers seeking alternative remedies.
- Curative Biosciences has a negative P/E ratio of -0.03, indicating it is not currently profitable.
- The company's market capitalization is $0.00B, reflecting its early stage and associated risks.
- Curative Biosciences exhibits a high beta of 64.72, suggesting significant volatility compared to the overall market.
Who Are CBDX's Competitors?
CBDX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AKAN Akanda Corp. | $1.89 | -1.05% | — | |
| SXTC China SXT Pharmaceuticals, Inc. | $1.55 | -25.48% | — | |
| GELS Gelteq Limited Ordinary Shares | $0.58 | +6.63% | $5.32M | — |
| SNOA Sonoma Pharmaceuticals, Inc. | $1.21 | -0.82% | $5.79M | — |
| APUS Apimeds Pharmaceuticals US, Inc. | $7.13 | +55.34% | $10.8M | — |
| BFRI Biofrontera Inc. | $0.93 | +4.61% | $11.9M | — |
| COSM COSM | $0.32 | -7.58% | $17.4M | — |
| QNTM Quantum BioPharma Ltd. | $3.25 | -0.47% | $20.8M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CBDX's Key Strengths?
Focus on high-growth medical cannabis industry.
- Potential for proprietary CBD formulations.
- Early mover advantage in emerging markets.
- Experienced management team.
What Are CBDX's Weaknesses?
Limited financial resources.
- Dependence on regulatory approvals.
- Intense competition from established players.
- Lack of clinical trial data to support product claims.
What Are the Key Risks for CBDX?
Changing regulatory landscape for cannabis products.
- Increased competition from larger companies.
- Negative public perception of cannabis products.
- Limited financial resources.
- Dependence on regulatory approvals.
What Are CBDX's Competitive Advantages?
- Proprietary CBD formulations.
- Strategic partnerships with healthcare providers.
- Early mover advantage in emerging markets.
- Strong brand reputation for quality and efficacy.
What Does CBDX Do?
Curative Biosciences, Inc., formerly known as Amaize Beverage Corporation, was founded in 2009 and rebranded in August 2017 to focus on the burgeoning medical cannabis industry. Headquartered in Miami, Florida, the company is dedicated to the development and commercialization of therapeutics derived from hemp-based Cannabidiol (CBD). Curative Biosciences intends to manufacture and market natural health products, positioning itself to serve a growing market segment seeking alternative and natural remedies. The company's strategy involves leveraging the therapeutic potential of CBD to create products that address various health and wellness needs. As a player in the specialty and generic drug manufacturing sector, Curative Biosciences navigates a complex regulatory landscape and competes with other companies exploring cannabinoid-based treatments. The company's success depends on its ability to innovate, secure regulatory approvals, and effectively market its products to consumers and healthcare professionals.
What Products and Services Does CBDX Offer?
- Develop therapeutics using hemp-derived Cannabidiol (CBD).
- Focus on the medical cannabis industry.
- Manufacture and market natural health products.
- Research and develop innovative CBD formulations.
- Target specific medical conditions with CBD-based treatments.
- Navigate the regulatory landscape for cannabis products.
- Seek strategic partnerships to expand market reach.
How Does CBDX Make Money?
- Develop and commercialize CBD-based therapeutics.
- Manufacture and sell natural health products.
- Generate revenue through product sales and licensing agreements.
- Invest in research and development to create proprietary formulations.
What Industry Does CBDX Operate In?
Curative Biosciences operates within the Drug Manufacturers - Specialty & Generic industry, which is experiencing growth due to increasing demand for specialized and affordable medications. The medical cannabis sector, in particular, is expanding rapidly as regulations surrounding cannabis and CBD products evolve. Companies like Curative Biosciences are positioning themselves to capitalize on this trend, but they face competition from established pharmaceutical companies and other emerging players. The industry is also subject to regulatory uncertainty and evolving consumer preferences, requiring companies to be agile and innovative.
Who Are CBDX's Key Customers?
- Consumers seeking natural health products.
- Patients seeking alternative treatments for medical conditions.
- Healthcare professionals interested in CBD-based therapies.
- Retailers and distributors of health and wellness products.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Curative Biosciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Miami, US. CBDX has traded publicly since 2004.
Key Financial Metrics
Return on equity for Curative Biosciences, Inc. stands at 8.5%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -49.6%, a gauge of the cash the business throws off relative to its market value.
CBDX Financials
CBDX Latest News
No recent news available for CBDX.
CBDX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CBDX.
Price Targets
Wall Street price target analysis for CBDX.
CBDX MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CBDX; grades run from A+ (80-100) to F (below 30).
Leadership: Katherine T. Alverson West
CEO
Katherine T. Alverson West serves as the Chief Executive Officer of Curative Biosciences, Inc. Her professional background includes experience in the healthcare and pharmaceutical sectors, with a focus on business development and strategic planning. She has previously held leadership positions in companies involved in the development and commercialization of pharmaceutical products. Her expertise lies in navigating the regulatory landscape and building strategic partnerships to drive growth and innovation.
Track Record: Under Katherine T. Alverson West's leadership, Curative Biosciences has focused on developing and commercializing therapeutics using hemp-derived Cannabidiol. She has overseen the company's efforts to manufacture and market natural health products within the medical cannabis industry. Her strategic decisions have aimed to position the company for growth in the evolving market for CBD-based treatments.
CBDX OTC Market Information
The OTC Other tier, also known as the Pink Sheets, represents the lowest tier of the OTC market. Companies in this tier often have limited or no financial disclosure, and may not meet minimum listing requirements. This tier is distinct from the NYSE or NASDAQ, which have stringent listing standards, including minimum share price, market capitalization, and financial reporting requirements. Companies on the OTC Other tier are generally considered to be higher risk due to the lack of transparency and regulatory oversight.
- OTC Tier: OTC Other
- Limited financial disclosure increases information asymmetry.
- Low trading volume and wide bid-ask spreads can lead to price volatility.
- Higher risk of fraud or manipulation due to less regulatory oversight.
- Potential for delisting or suspension of trading.
- Difficulty in obtaining accurate and timely company information.
- Verify the company's legal status and registration.
- Obtain and review any available financial statements.
- Assess the company's management team and their experience.
- Research the company's products and market position.
- Evaluate the regulatory environment and potential risks.
- Determine the liquidity of the stock and potential trading difficulties.
- Consult with a financial advisor before investing.
- Company's focus on developing and commercializing therapeutics.
- Involvement in the medical cannabis industry.
- Efforts to manufacture and market natural health products.
- CEO with experience in the healthcare and pharmaceutical sectors.
- Company's history of operating since 2009.
Curative Biosciences, Inc. Healthcare Stock: Key Questions Answered
What do analysts say about CBDX stock?
As of March 18, 2026, there is no readily available analyst coverage for Curative Biosciences, Inc. (CBDX). Given its OTC Other tier listing and limited market capitalization, the company may not be actively tracked by major brokerage firms.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Information is based on available data as of March 18, 2026.
- OTC market data may be limited or unreliable.